Literature DB >> 6090169

In vivo determination of efficacy of pyrazoloquinolinones at the benzodiazepine receptor.

C Brown, I Martin, B Jones, N Oakley.   

Abstract

The pyrazoloquinolinones CGS 9896, CGS 9895 and CGS 8216 potently displace the benzodiazepines from their CNS binding site in vitro but have been reported to display agonist, partial agonist and antagonist activity respectively in a number of in vivo tests in rats. We found CGS 9896 to have only weak antipentylenetetrazole activity in mice at doses which produced near maximal displacement of [3H]flunitrazepam in vivo and were not able to detect any antipentylenetetrazole activity of CGS 9895. However, CGS 9895 blocked the anticonvulsant effect of diazepam at doses closely related to those which inhibited the in vivo binding of [3H]flunitrazepam and CGS 9896 also showed some reversal of the antipentylenetetrazole action of diazepam. This is consistent with the notion that CGS 9896 is a partial agonist and CGS 9895 an antagonist at the benzodiazepine receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090169     DOI: 10.1016/0014-2999(84)90200-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Effects of non-sedative anxiolytic drugs on responses to GABA and on diazepam-induced enhancement of these responses on mouse neurones in cell culture.

Authors:  P P De Deyn; R L Macdonald
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

2.  Benzodiazepine-induced hyperphagia: stereospecificity and antagonism by pyrazoloquinolines, CGS 9895 and CGS 9896.

Authors:  S J Cooper; R E Yerbury
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Pharmacologic profile of a new anxiolytic, DN-2327: effect of Ro15-1788 and interaction with diazepam in rodents.

Authors:  T Wada; N Fukuda
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Subtype selectivity of α+β- site ligands of GABAA receptors: identification of the first highly specific positive modulators at α6β2/3γ2 receptors.

Authors:  Zdravko Varagic; Joachim Ramerstorfer; Shengming Huang; Sundari Rallapalli; Isabella Sarto-Jackson; James Cook; Werner Sieghart; Margot Ernst
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

5.  The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs.

Authors:  Joachim Ramerstorfer; Roman Furtmüller; Isabella Sarto-Jackson; Zdravko Varagic; Werner Sieghart; Margot Ernst
Journal:  J Neurosci       Date:  2011-01-19       Impact factor: 6.167

6.  Identification of novel positive allosteric modulators and null modulators at the GABAA receptor α+β- interface.

Authors:  Zdravko Varagic; Laurin Wimmer; Michael Schnürch; Marko D Mihovilovic; Shengming Huang; Sundari Rallapalli; James M Cook; Pantea Mirheydari; Gerhard F Ecker; Werner Sieghart; Margot Ernst
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.